Amylyx Pharmaceuticals entered into a Manufacturing and Supply Agreement with Bachem Americas to supply avexitide drug substance for commercial use starting in 2028, alongside a term sheet with Polypeptide Group AG requiring a $30 million upfront fee for capacity reservation. Both agreements establish non-exclusive supply arrangements with minimum purchase quantities and annual price adjustments effective January 1, 2028. The company operates in the pharmaceutical industry, focusing on drug development.
